Plain-English translation of NCT06671483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help people with psoriatic arthritis—a condition where the joints and skin become inflamed and painful. About 1,088 people will join this study across multiple hospitals. Some participants will receive the medication at different doses, some will receive an existing arthritis treatment, and some will start with a placebo before receiving the new medication later.
Psoriatic arthritis can be very painful and damaging to joints if not treated well. While some biologic medications exist, they don't work for everyone and can be difficult to use. This trial will help doctors understand whether this medication offers a new, easier option for people who haven't tried biologic treatments yet.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill by mouth for up to 52 weeks, and the study lasts up to 60 weeks total. Depending on which group you're randomly assigned to, you might receive the new medication at one of two doses, a currently approved arthritis medication, or a placebo (fake pill) for the first 16 weeks followed by the new medication. You'll have regular visits with the research team to check how you're doing, measure your joint swelling and tenderness, and watch for any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States